Key Takeaways
- • Ensysce Biosciences completed the acquisition of Cy Biopharma and secured up to $77 million in private financing, consisting of $21.5 million at initial close plus $17.1 million in cash from Cy Biopharma's pre-acquisition convertible note financing, with an additional $38.6 million contingent on clinical trial milestones.
- • The Series C non-voting convertible preferred stock offering was led by Ally Bridge Group and included participation from Perceptive Advisors, Dellora Investments, Ikarian Capital, and Adage Capital Partners, with shares priced at $321.79 per share.
- • The acquisition brings CY200, a clinical-stage neuroplastogenic therapy with FDA Orphan Drug Designation for treatment of Complex Regional Pain Syndrome (CRPS), into Ensysce's portfolio, expanding the company's focus beyond mood disorders into complex pain indications.
- • Pro forma cash position is expected to fund CY200 development through Phase 2 proof-of-concept data and into registrational development, with the contingent tranche designed to support development into 2028.
- • Approximately $31 million in net proceeds closed post-quarter, with the follow-on tranche of up to $38.6 million contingent upon achievement of pre-defined clinical trial milestones.
Summary
Ensysce Biosciences completed its acquisition of Cy Biopharma, a privately held clinical-stage biotechnology company, concurrent with securing a substantial private financing round totaling up to $77 million. The transaction structure combined immediate cash proceeds with milestone-based contingent funding, providing the combined entity with significant runway to advance Cy Biopharma's neuroplastogenic drug program.
The financing consisted of three key components: an initial $21.5 million private placement of Series C non-voting convertible preferred stock (with 1:1,000 conversion ratio to common shares) priced at $321.79 per share; $17.1 million in cash brought in from Cy Biopharma's pre-acquisition convertible note financing; and up to $38.6 million in contingent proceeds tied to achievement of clinical development milestones. The transaction closed with approximately $31 million in net proceeds recorded post-quarter, with the milestone-contingent tranche designed to extend funding visibility through 2028.
The financing syndicate was led by Ally Bridge Group and included participation from institutional investors Perceptive Advisors, Dellora Investments, Ikarian Capital, and Adage Capital Partners. This investor composition signals institutional confidence in Ensysce's expanded clinical pipeline and development strategy.
Cy Biopharma's lead asset, CY200, is a clinical-stage neuroplastogenic therapy that has received FDA Orphan Drug Designation for Complex Regional Pain Syndrome (CRPS), a rare and debilitating pain condition. The acquisition represents Ensysce's strategic expansion beyond its historical focus on mood disorders into the underserved complex pain indication space. The combined entity's pro forma cash position is positioned to fund CY200 through Phase 2 proof-of-concept data generation and into registrational development pathways.
This financing structure—combining upfront capital with performance-based tranches—aligns investor incentives with clinical progress while providing Ensysce with predictable capital deployment through key inflection points in the drug development cycle.
The financing consisted of three key components: an initial $21.5 million private placement of Series C non-voting convertible preferred stock (with 1:1,000 conversion ratio to common shares) priced at $321.79 per share; $17.1 million in cash brought in from Cy Biopharma's pre-acquisition convertible note financing; and up to $38.6 million in contingent proceeds tied to achievement of clinical development milestones. The transaction closed with approximately $31 million in net proceeds recorded post-quarter, with the milestone-contingent tranche designed to extend funding visibility through 2028.
The financing syndicate was led by Ally Bridge Group and included participation from institutional investors Perceptive Advisors, Dellora Investments, Ikarian Capital, and Adage Capital Partners. This investor composition signals institutional confidence in Ensysce's expanded clinical pipeline and development strategy.
Cy Biopharma's lead asset, CY200, is a clinical-stage neuroplastogenic therapy that has received FDA Orphan Drug Designation for Complex Regional Pain Syndrome (CRPS), a rare and debilitating pain condition. The acquisition represents Ensysce's strategic expansion beyond its historical focus on mood disorders into the underserved complex pain indication space. The combined entity's pro forma cash position is positioned to fund CY200 through Phase 2 proof-of-concept data generation and into registrational development pathways.
This financing structure—combining upfront capital with performance-based tranches—aligns investor incentives with clinical progress while providing Ensysce with predictable capital deployment through key inflection points in the drug development cycle.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.